Glycoprotein (GP) IIb-IIIa antagonists inhibit the aggregation of activated platelets. GP IIb-IIIa antagonists have greatest benefit when used as adjunctive therapy during percutaneous coronary intervention (PCI) when the patient has intra-coronary thrombosis

Glycoprotein (GP) IIb-IIIa antagonists inhibit the aggregation of activated platelets. GP IIb-IIIa antagonists have greatest benefit when used as adjunctive therapy during percutaneous coronary intervention (PCI) when the patient has intra-coronary thrombosis

Type of document           Essay     1 Page  Subject area         Nursing              Academic Level Master

Style      APA       references          2

Order description:

U8D1

COLLAPSE

“Glycoprotein (GP) IIb-IIIa antagonists inhibit the aggregation of activated platelets. GP IIb-IIIa antagonists have greatest benefit when used as adjunctive therapy during percutaneous coronary intervention (PCI) when the patient has intra-coronary thrombosis. These agents appear to provide greatest benefit when used in combination with heparin.” (Schneider, 2011, p. 672) Drugs that fall into this class include abciximab (Reopro), tirofiban (Aggrastat), and eptifibatide (Integrilin). Their mechanism of action is to “inhibit platelet aggregation by reversibly binding to the platelet receptor glycoprotein IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands.” (Micromedex, 2017)

 

Our cath lab’s use of these drugs varies by interventional cardiologist. We occasionally use Integrilin and Aggrastat , and more commonly use Reopro. One of these class of drugs is used for every PCI, to prevent clot formation and further damage to the patient including stroke, pulmonary embolus, further cardiac damage, and other thrombotic events. I am unaware of any other specialties utilizing this class of drugs, so I would love to see other student’s discussion on this topic. Is it used for Neurointervention for thrombectomy in the brain, for large vessel occlusions?

References

Micromedex. (2017). Glcoprotein IIb/IIIa antagonist. (Version 1.79.2b2680) [Mobile application software]. Retrieved from micromedexsolutions.com

 

Schneider, D. (2011). Anti-platelet therapy: glycoprotein IIb-IIa antagonists. British Journal of Clinical Pharmacolgy , 72(4), 672-682. https://doi.org/10.1111/j.1365-2125.2010

 

** Provide response with references, in APA format and within the last 5 years